InsidersTradesSigma
Total declarations
Companies
▲ Purchases (23 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
23
Disclosed sells
0
T+90 hit rate
35%
T+90 mean return
-6.5%
Across 23 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Manning Paul B, Director. Director active across 6 companies, notably Taysha Gene Therapies, Inc.. Cumulatively, 32 disclosures have been recorded. Breakdown: 23 buys · 0 sell. Total volume traded: €42.2m. Activity tracked since 14 May 2021. The latest transaction was disclosed on 16 December 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations32 total
500,000 shares@ US$6.0086.4% of flowCommon StockSEC:0000950170-24-137889:0
Ideal exit: 12 Sept 2025 (T+270)
18,426,966 sharesCommon StockSEC:0001415889-24-027709:0
Ideal exit: 19 Aug 2025 (T+270)
2,675,611.25 shares0Common StockSEC:0001415889-24-023835:0
337,078 shares@ US$8.9042.3% of flowCommon StockSEC:0001104659-24-100179:0
Ideal exit: 9 Jun 2025 (T+270)
1,333,333 shares@ US$2.2513.3% of flowCommon StockSEC:0001415889-24-018515:0
Ideal exit: 24 Mar 2025 (T+270)
20,359 shares0Common StockSEC:0001104659-24-074473:0
279,330 shares@ US$7.1628.7% of flowCommon StockSEC:0001104659-23-126932:0
Ideal exit: 9 Sept 2024 (T+270)
100,000 shares@ US$1.630.7% of flowCommon StockSEC:0001209191-23-055942:0
Ideal exit: 13 Aug 2024 (T+270)
16,466,667 shares@ US$0.9064.6% of flowCommon StockSEC:0001209191-23-046154:0
Ideal exit: 12 May 2024 (T+270)
200,000 shares@ US$5.028.1% of flowCommon StockSEC:0001209191-23-043255:0
Ideal exit: 19 Apr 2024 (T+270)
1,500,000 shares@ US$2.0014.3% of flowCommon StockSEC:0001209191-22-055263:0
Ideal exit: 28 Jul 2023 (T+270)
4,761,904 shares@ US$2.1087.4% of flowCommon StockSEC:0001209191-22-040581:0
Ideal exit: 1 Apr 2023 (T+270)
435,674 shares0Common StockSEC:0001104659-22-047871:0
392,156 shares@ US$5.100.037% mcap100.0% of flowCommon StockSEC:0001104659-22-047360:0
Ideal exit: 13 Jan 2023 (T+270)
58,000 shares@ US$7.770.023% mcap26.5% of flowCommon StockSEC:0001209191-22-007126:0
Ideal exit: 30 Oct 2022 (T+270)
58,000 shares@ US$7.770.023% mcap61.6% of flowCommon StockSEC:0001209191-22-007126
Ideal exit: 30 Oct 2022 (T+270)
30,023 shares@ US$9.45100.0% of flowCommon StockSEC:0001209191-21-068031
Ideal exit: 29 Aug 2022 (T+270)
30,023 shares@ US$9.450.23% mcap50.0% of flowCommon StockSEC:0001209191-21-068031:0
Ideal exit: 29 Aug 2022 (T+270)
2,202 shares@ US$13.190.0015% mcap1.7% of flowCommon StockSEC:0001209191-21-067005:0
Ideal exit: 21 Aug 2022 (T+270)
2,202 shares@ US$13.194.0% of flowCommon StockSEC:0001209191-21-067005
Ideal exit: 21 Aug 2022 (T+270)
20,000 shares@ US$12.5434.4% of flowCommon StockSEC:0001209191-21-066702
Ideal exit: 20 Aug 2022 (T+270)
20,000 shares@ US$12.540.013% mcap14.8% of flowCommon StockSEC:0001209191-21-066702:0
Ideal exit: 20 Aug 2022 (T+270)
679,158 sharesCommon StockSEC:0000899243-21-031614
679,158 sharesCommon StockSEC:0000899243-21-031614:0
679,158 sharesCommon StockSEC:0000899243-21-031096
25 of 32 declarations
About Manning Paul B
Manning Paul B is an executive at Taysha Gene Therapies, Inc.
